Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
Reena J. Salgia, MD, discusses the advantages of utilizing an atezolizumab plus bevacizumab backbone as standard frontline therapy in unresectable HCC; how factors such as Child-Pugh B score, bleeding, and other high-risk features impact treatment selection; and the unmet needs that still need to be addressed for this patient population.
The combination comprised of camrelizumab and famitinib showcased improved efficacy with a manageable safety profile vs camrelizumab monotherapy or investigator’s choice of chemotherapy in patients with recurrent or metastatic cervical cance.
The Center for Drug Evaluation of China’s National Medical Products Administration has accepted and granted priority review to the new drug application for IBI351 in the treatment of patients with advanced, KRAS G12C–mutant NSCLC who have received at least 1 prior systemic therapy.
Nimotuzumab given concurrently with chemoradiotherapy demonstrated efficacy and favorable tolerability in patients with locally advanced cervical squamous cell carcinoma, according to data from a randomized, controlled, open-label, multicenter study.
Retifanlimab-dlwr continued to elicit responses with acceptable tolerability in patients with recurrent microsatellite instability–high or mismatch–repair deficient endometrial cancer, according to final findings from cohort H of the phase 1 POD1UM-101 trial.
Benjamin Philip Levy, MD, discusses the current landscape of emerging antibody-drug conjugates (ADCs) and their early activity in advanced lung cancer, the potential utility of oncogene-directed ADCs for patients with driver mutations, and more.
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.
New Cleveland Clinic research reveals how BRCA1 and BRCA2 gene mutations may impact cell communication in breast tissue, furthering the understanding of how cancer develops.
The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.
Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.
The European Medicines Agency has validated a type II application for the investigational T-cell engaging bispecific antibody epcoritamab-bysp for patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of therapy
Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.
Drs Camidge and McVeigh highlight the evolution of the clinical genetics field over time, the process of identifying pathogenic genetic variants, the difficulties of explaining genetic testing results to patients, and more.
The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.
A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.
Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial.
Subgroup analyses from non–small cell lung cancer clinical trials, such as the phase 3 POSEIDON and FLAURA2 trials, can help personalize treatment decisions with immunotherapy and targeted therapy based on individual mutational profiles.
Marc J. Braunstein, MD, PhD, discusses the current role of autologous stem cell transplant for patients with multiple myeloma, highlighted the key factors used to determine patient eligibility, and detailed ongoing research centered around autologous stem cell transplant.
Edna “Eti” Cukierman, PhD, Co-Director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute and Co-Leader of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently awarded the American Cancer Society’s Wilmott Family Professorship in Pancreatic Cancer.
Aumolertinib plus anlotinib resulted in intracranial efficacy when used in the first-line treatment of patients with EGFR-mutant non–small cell lung cancer who have brain metastases.
Elizabeth Plimack, MD, MS, Deputy Director and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently recognized as a new fellow of the American Society of Clinical Oncology.